Syngene International Limited has announced significant changes to its Board of Directors. The company has approved the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Additional Directors (Independent, Non-Executive) for three-year terms. Additionally, the Board approved the reappointment of Ms. Vinita Bali as a Non-Executive Director for one year. These strategic appointments, effective from the upcoming 33rd Annual General Meeting, reflect the company’s commitment to strong leadership and corporate governance.
New Independent Director Appointments
The company is strengthening its board oversight with the addition of two industry veterans. Mr. Vijaya Chandru, an academic-entrepreneur with deep expertise in artificial intelligence and computational biology, and Mr. Arun Chandavarkar, former CEO & Joint Managing Director of Biocon Limited, have been appointed as Additional Directors. Their terms are set for three years, commencing from the conclusion of the 33rd Annual General Meeting scheduled for July 29, 2026.
Leadership Continuity
In addition to these new appointments, the board has solidified its existing leadership structure through the reappointment of Ms. Vinita Bali. A seasoned global business leader, Ms. Bali will continue her role as a Non-Executive Director for a further period of one year, effective from July 22, 2026, until July 21, 2027. Ms. Bali currently serves on key board committees, including the Audit and Nomination & Remuneration Committees.
Expertise and Strategic Impact
The incoming directors bring a wealth of diverse experience to the firm. Mr. Chandru contributes extensive research and technology leadership, while Mr. Chandavarkar offers significant biopharma industry insight, having played a pivotal role in the transformation of Biocon into a global entity. These leadership updates are subject to final approval by the shareholders, marking a proactive step in maintaining robust governance standards at Syngene International.
Source: BSE
